CN109996540A - (r)-2-氨基-3-苯丙基氨基甲酸酯的溶剂化物形式 - Google Patents
(r)-2-氨基-3-苯丙基氨基甲酸酯的溶剂化物形式 Download PDFInfo
- Publication number
- CN109996540A CN109996540A CN201780065192.6A CN201780065192A CN109996540A CN 109996540 A CN109996540 A CN 109996540A CN 201780065192 A CN201780065192 A CN 201780065192A CN 109996540 A CN109996540 A CN 109996540A
- Authority
- CN
- China
- Prior art keywords
- phenylpropylamino
- amino
- formic acid
- acid ester
- ester hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202511369602.9A CN121202730A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途 |
| CN202510706413.XA CN120574152A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的溶剂化物形式的晶体、其制备方法、组合物及用途 |
| CN202511369712.5A CN121202731A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的晶体、其组合物及用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383822P | 2016-09-06 | 2016-09-06 | |
| US62/383,822 | 2016-09-06 | ||
| PCT/US2017/050233 WO2018048871A1 (en) | 2016-09-06 | 2017-09-06 | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511369712.5A Division CN121202731A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的晶体、其组合物及用途 |
| CN202510706413.XA Division CN120574152A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的溶剂化物形式的晶体、其制备方法、组合物及用途 |
| CN202511369602.9A Division CN121202730A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109996540A true CN109996540A (zh) | 2019-07-09 |
Family
ID=61562003
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780065192.6A Pending CN109996540A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯的溶剂化物形式 |
| CN202511369602.9A Pending CN121202730A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途 |
| CN202511369712.5A Pending CN121202731A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的晶体、其组合物及用途 |
| CN202510706413.XA Pending CN120574152A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的溶剂化物形式的晶体、其制备方法、组合物及用途 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511369602.9A Pending CN121202730A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途 |
| CN202511369712.5A Pending CN121202731A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的晶体、其组合物及用途 |
| CN202510706413.XA Pending CN120574152A (zh) | 2016-09-06 | 2017-09-06 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的溶剂化物形式的晶体、其制备方法、组合物及用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10829443B2 (https=) |
| EP (2) | EP3509582B1 (https=) |
| JP (3) | JP7219213B2 (https=) |
| KR (1) | KR102513800B1 (https=) |
| CN (4) | CN109996540A (https=) |
| CA (1) | CA3036071A1 (https=) |
| DK (1) | DK3509582T3 (https=) |
| ES (1) | ES2970887T3 (https=) |
| FI (1) | FI3509582T3 (https=) |
| MY (1) | MY197630A (https=) |
| PH (1) | PH12019500493A1 (https=) |
| SG (1) | SG11201901998WA (https=) |
| WO (1) | WO2018048871A1 (https=) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY197630A (en) | 2016-09-06 | 2023-06-29 | Sk Biopharmaceuticals Co Ltd | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| WO2020035769A1 (en) | 2018-08-14 | 2020-02-20 | Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
| WO2021001457A1 (en) | 2019-07-04 | 2021-01-07 | Sandoz Ag | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts |
| IT202000013855A1 (it) | 2020-06-10 | 2021-12-10 | Flamma Spa | Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato |
| AU2023375326A1 (en) * | 2022-11-07 | 2025-05-22 | Axsome Therapeutics | Compositions and methods for treating insomnia |
| WO2024145545A2 (en) * | 2022-12-30 | 2024-07-04 | Axsome Malta Ltd. | Methods of administering solriamfetol to lactating women |
| WO2024194718A1 (en) | 2023-03-22 | 2024-09-26 | Unichem Laboratories Limited | A stable pharmaceutical composition and process for preparing thereof |
| CN121816178A (zh) | 2023-05-30 | 2026-04-07 | 艾克萨姆治疗股份有限公司 | 用于治疗患有与阻塞性睡眠呼吸暂停和白天过度嗜睡相关的认知受损的受试者的认知受损的索安非托 |
| KR20260033050A (ko) | 2023-06-29 | 2026-03-10 | 액섬 테라퓨틱스, 인크. | 수유 여성에게 솔리암페톨을 투여하는 방법 |
| WO2025042959A1 (en) | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
| WO2025165760A1 (en) * | 2024-01-29 | 2025-08-07 | Axsome Therapeutics, Inc. | Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1135209A (zh) * | 1994-09-09 | 1996-11-06 | 株式会社油公 | 新的氨基甲酸苯基烷基氨基醇酯及其制备方法 |
| WO2007001841A1 (en) * | 2005-06-22 | 2007-01-04 | Sk Holdings Co., Ltd. | Treatment of sexual dysfunction |
| CN101217949A (zh) * | 2005-06-08 | 2008-07-09 | Sk株式会社 | 治疗睡眠-清醒病症 |
| CN105873576A (zh) * | 2013-07-18 | 2016-08-17 | 爵士制药国际Iii有限公司 | 治疗肥胖 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| DK1140061T3 (da) | 1998-12-23 | 2003-08-25 | Orphan Medical Inc | Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi |
| RU2202607C2 (ru) | 2000-03-03 | 2003-04-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" | Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина |
| US20050080268A1 (en) * | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| RU2007119648A (ru) | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| BR112012010670A2 (pt) | 2009-11-06 | 2016-04-12 | Sk Biopharmaceuticals Co Ltd | métodos para tratamento de distúrbio de défict de atenção/hiperatividade |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| CA2905457A1 (en) | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
| JP2016530240A (ja) | 2013-07-12 | 2016-09-29 | ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ | 禁煙の促進 |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| MY197630A (en) * | 2016-09-06 | 2023-06-29 | Sk Biopharmaceuticals Co Ltd | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| KR101950254B1 (ko) | 2016-09-21 | 2019-02-20 | 유상신 | 차량탑승자의 부재를 감지하는 지능형 카시트 |
| WO2020035769A1 (en) * | 2018-08-14 | 2020-02-20 | Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
-
2017
- 2017-09-06 MY MYPI2019001180A patent/MY197630A/en unknown
- 2017-09-06 CN CN201780065192.6A patent/CN109996540A/zh active Pending
- 2017-09-06 EP EP17849432.4A patent/EP3509582B1/en active Active
- 2017-09-06 US US16/331,069 patent/US10829443B2/en active Active
- 2017-09-06 ES ES17849432T patent/ES2970887T3/es active Active
- 2017-09-06 CN CN202511369602.9A patent/CN121202730A/zh active Pending
- 2017-09-06 SG SG11201901998WA patent/SG11201901998WA/en unknown
- 2017-09-06 DK DK17849432.4T patent/DK3509582T3/da active
- 2017-09-06 WO PCT/US2017/050233 patent/WO2018048871A1/en not_active Ceased
- 2017-09-06 FI FIEP17849432.4T patent/FI3509582T3/fi active
- 2017-09-06 CN CN202511369712.5A patent/CN121202731A/zh active Pending
- 2017-09-06 JP JP2019512895A patent/JP7219213B2/ja active Active
- 2017-09-06 CA CA3036071A patent/CA3036071A1/en not_active Abandoned
- 2017-09-06 CN CN202510706413.XA patent/CN120574152A/zh active Pending
- 2017-09-06 KR KR1020197011279A patent/KR102513800B1/ko active Active
- 2017-09-06 EP EP23218015.8A patent/EP4364794A3/en active Pending
-
2019
- 2019-03-06 PH PH12019500493A patent/PH12019500493A1/en unknown
-
2020
- 2020-11-06 US US17/091,222 patent/US11560354B2/en active Active
-
2021
- 2021-09-24 JP JP2021155292A patent/JP7642506B2/ja active Active
-
2022
- 2022-12-14 US US18/066,000 patent/US12384743B2/en active Active
-
2024
- 2024-09-19 JP JP2024161956A patent/JP2024178291A/ja active Pending
-
2025
- 2025-07-11 US US19/266,767 patent/US20250340509A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1135209A (zh) * | 1994-09-09 | 1996-11-06 | 株式会社油公 | 新的氨基甲酸苯基烷基氨基醇酯及其制备方法 |
| CN101217949A (zh) * | 2005-06-08 | 2008-07-09 | Sk株式会社 | 治疗睡眠-清醒病症 |
| WO2007001841A1 (en) * | 2005-06-22 | 2007-01-04 | Sk Holdings Co., Ltd. | Treatment of sexual dysfunction |
| CN105873576A (zh) * | 2013-07-18 | 2016-08-17 | 爵士制药国际Iii有限公司 | 治疗肥胖 |
Non-Patent Citations (1)
| Title |
|---|
| 劳芳 等: "从专利无效、行政诉讼的案例看药物晶型的创造性", 《中国发明与专利》 * |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128021B1 (en) | 2016-07-22 | 2024-10-29 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263151B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097176B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097175B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12109186B2 (en) | 2016-07-22 | 2024-10-08 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115142B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115144B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115143B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115145B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12239625B2 (en) | 2016-07-22 | 2025-03-04 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12138239B2 (en) | 2016-07-22 | 2024-11-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12144793B2 (en) | 2016-07-22 | 2024-11-19 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263150B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12257223B2 (en) | 2016-07-22 | 2025-03-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186298B2 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226389B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226388B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics |
| US12226377B2 (en) | 2019-03-01 | 2025-02-18 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167992B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167991B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12303478B2 (en) | 2019-03-01 | 2025-05-20 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12295926B1 (en) | 2022-02-07 | 2025-05-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US12551457B1 (en) | 2022-02-07 | 2026-02-17 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
| Publication number | Publication date |
|---|---|
| CN120574152A (zh) | 2025-09-02 |
| SG11201901998WA (en) | 2019-04-29 |
| JP7219213B2 (ja) | 2023-02-07 |
| EP3509582A1 (en) | 2019-07-17 |
| JP7642506B2 (ja) | 2025-03-10 |
| CA3036071A1 (en) | 2018-03-15 |
| US20250340509A1 (en) | 2025-11-06 |
| EP3509582A4 (en) | 2020-05-13 |
| MY197630A (en) | 2023-06-29 |
| US12384743B2 (en) | 2025-08-12 |
| EP4364794A2 (en) | 2024-05-08 |
| US20230183172A1 (en) | 2023-06-15 |
| US10829443B2 (en) | 2020-11-10 |
| DK3509582T3 (en) | 2024-02-12 |
| WO2018048871A1 (en) | 2018-03-15 |
| FI3509582T3 (fi) | 2024-02-08 |
| KR20190065311A (ko) | 2019-06-11 |
| US20210053912A1 (en) | 2021-02-25 |
| JP2022003062A (ja) | 2022-01-11 |
| JP2024178291A (ja) | 2024-12-24 |
| CN121202730A (zh) | 2025-12-26 |
| US20190194126A1 (en) | 2019-06-27 |
| EP4364794A3 (en) | 2024-07-24 |
| CN121202731A (zh) | 2025-12-26 |
| JP2019535643A (ja) | 2019-12-12 |
| EP3509582B1 (en) | 2023-12-20 |
| PH12019500493A1 (en) | 2019-05-27 |
| ES2970887T3 (es) | 2024-05-31 |
| US11560354B2 (en) | 2023-01-24 |
| KR102513800B1 (ko) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12384743B2 (en) | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | |
| CN103958469B (zh) | 一种新的普利多匹定盐酸盐多晶型形态 | |
| CN101597272B (zh) | 艾拉莫德的钾盐化合物,其制备方法和药物应用 | |
| JP6203170B2 (ja) | アゴメラチンの新しい結晶形ｖｉｉ、その調製方法及び使用並びにこれを含有する医薬組成物 | |
| WO2011047767A1 (en) | Novel polymorphic forms of (s)-2-[-4-(3-fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof | |
| KR20140111044A (ko) | 구연산아일데나필 결정 형태 o 및 그의 제조방법과 용도 | |
| ES2587064T3 (es) | Sales fumarato novedosas de un antagonista del receptor de histamina H3 | |
| JP6610793B2 (ja) | 環状アミン誘導体の結晶及びその医薬用途 | |
| CN101671338A (zh) | 枸橼酸爱地那非晶型d及其制备方法和用途 | |
| JP4015954B2 (ja) | トシル酸スプラタスト結晶 | |
| CN101993417A (zh) | 磷酸二甲啡烷的稳定新晶型 | |
| HK40009279A (en) | Solvate form of (r)-2-amino-3-phenylpropyl carbamate | |
| JPH02237928A (ja) | 置換ベンズアミドより成る胃の自動運動性増進用薬剤 | |
| CN105315230B (zh) | 无定型形态的匹维溴铵 | |
| CN113861185B (zh) | 2-(取代的嘧啶基)噻唑甲酰胺化合物的盐及其组合物和用途 | |
| WO2025170483A1 (ru) | Фармацевтическая композиция, обладающая антибиотической активностью | |
| WO2018090360A1 (zh) | 一种三芳基二甲基哌嗪二盐酸盐的多晶型物及其制备方法和应用 | |
| CN106316917A (zh) | Lu AE58054的盐酸盐晶型B及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40009279 Country of ref document: HK |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221117 Address after: Irish Dublin Applicant after: Gaz Pharmaceutical Co.,Ltd. Applicant after: SK BIOPHARMACEUTICALS Co.,Ltd. Address before: Bermuda Hamilton Applicant before: JAZZ PHARMACEUTICALS INTERNATIONAL III Ltd. Applicant before: SK BIOPHARMACEUTICALS Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190709 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 40009279 Country of ref document: HK |